Baishideng Publishing Group Co., Limited
Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report
Name of Journal: World Journal of Hepatology
ESPS Manuscript NO: 4929
Title: Compounds able to control hepatic cholesterol metabolism: is it possible to avoid statin treatment in aged people?
Reviewer code: 01561119
Science editor: Zhai, Huan-Huan
Date sent for review: 2013-08-03 22:49
Date reviewed: 2013-08-09 12:55

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
[Y] Grade A (Excellent)	[Y] Grade A: Priority Publishing	Google Search:	[Y] Accept
[ ] Grade B (Very good)	[ ] Grade B: minor language polishing	[ ] Existed	[ ] High priority for publication
[ ] Grade C (Good)	[ ] Grade C: a great deal of language polishing	[ ] No records	[ ]Rejection
[ ] Grade D (Fair)	[ ] Grade D: rejected	BPG Search:	[ ] Minor revision
[ ] Grade E (Poor)		[ ] Existed	[ ] Major revision
		[ ] No records	

COMMENTS TO AUTHORS
I am pleased to inform you that your review manuscript 'New compounds able to control hepatic cholesterol metabolism: is it possible to avoid statin treatment in aged peple?' has been accepted for publication in World Journal of Hepatology. This MS is well-organized and stated clearly. It may open fresh avenue for the advanced therapeutic strategies. Thank you very much.

Baishideng Publishing Group Co., Limited
Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report
Name of Journal: World Journal of Hepatology
ESPS Manuscript NO: 4929
Title: Compounds able to control hepatic cholesterol metabolism: is it possible to avoid statin treatment in aged people?
Reviewer code: 02440657
Science editor: Zhai, Huan-Huan
Date sent for review: 2013-08-03 22:49
Date reviewed: 2013-08-15 06:08

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
[ ] Grade A (Excellent)	[Y] Grade A: Priority Publishing	Google Search:	[Y] Accept
[Y] Grade B (Very good)	[ ] Grade B: minor language polishing	[ ] Existed	[ ] High priority for publication
[ ] Grade C (Good)	[ ] Grade C: a great deal of language polishing	[ ] No records	[ ]Rejection
[ ] Grade D (Fair)	[ ] Grade D: rejected	BPG Search:	[ ] Minor revision
[ ] Grade E (Poor)		[ ] Existed	[ ] Major revision
		[ ] No records	

COMMENTS TO AUTHORS
The review manuscript "New compounds able to control hepatic cholesterol metabolism: is it possible to avoid statin treatment in aged people?" is quite informative, targeting the potential cholesterol-lowering compounds available, the authors describe and evaluate both the promising application and side effect. Conslusions of clinical trials as well as experimental data are analyzed in the manuscript, providing a very inclusive update of this area. The work can be more remarkable if a table is provided to compare the difference of compounds in treating hypercholesterolemia in aged people or animals, or a model is drawn to show the variable mechanisms. The information from literature maybe limited, but if include any studies that compare other compounds with statin would be better.

Baishideng Publishing Group Co., Limited
Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report
Name of Journal: World Journal of Hepatology
ESPS Manuscript NO: 4929
Title: Compounds able to control hepatic cholesterol metabolism: is it possible to avoid statin treatment in aged people?
Reviewer code: 01800318
Science editor: Zhai, Huan-Huan
Date sent for review: 2013-08-03 22:49
Date reviewed: 2013-08-16 19:06

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
[ ] Grade A (Excellent)	[Y] Grade A: Priority Publishing	Google Search:	[ ] Accept
[ ] Grade B (Very good)	[ ] Grade B: minor language polishing	[ ] Existed	[ ] High priority for publication
[Y] Grade C (Good)	[ ] Grade C: a great deal of language polishing	[ ] No records	[ ]Rejection
[ ] Grade D (Fair)	[ ] Grade D: rejected	BPG Search:	[ ] Minor revision
[ ] Grade E (Poor)		[ ] Existed	[Y] Major revision
		[ ] No records	

COMMENTS TO AUTHORS
It is a well-written paper, however authors should improve its content according to the following comments: 1) Since they refer many categories of antihypolipidaemic agents they should create an appropriate table for each category in which they will add all the necessary informations/data. It will be great if they create tables separately for experimental and clinical data in order the text to be more concise and comprehensible. 2) There is a lack with regard the categories of antihypolipidaemic agents, since there is no mention regarding sterols and stanols and synthetic PPAR-γ agonists 3) Also there is no mention to substances as orlistat which act to obesity and subsequently can improve plasma lipids concentrations and fatty liver. 4) The role of folic acid as an antioxidant and antiatherosclerotic agent should also be referred. 5) Regarding the fibrates and their mechanism of action as hypolipidemic drugs, there is mention only for the triglyceride, so authors should add their effect on total cholesterol and LDL-cholesterol levels. 6) It would be interesting and helpful to provide the most updated data to the readers, if authors could mention the debated role of vit. D to the hypolipidemic parameters as well as the role of nutraceuticals (monakolines, berberine and gargle extracts). 7) Furthermore, authors should refer the role of human polymorphisms on drugs action-especially of statins- since it is well-known that the type of polymorphism could determine the effect of drugs on lipid parameters, especially on LDL-Cholesterol plasma levels. 8) Also, authors should mention in detail all the mechanisms in which statins act on lipids levels, such as the inhibition of ion countertransports (Na-Li countertransport activity, etc). 9) Finally, some additional epidemiological data should be mentioned, since dyslipidemia affects, not only in the coronary vessels, but also in carotides and the brain vessels! For all my comments, authors should

read and use the appropriate data from the following suggesting papers ing these comments on my article. Statins, bone formation and osteoporosis: hope or hype? Tsartsalis AN, Dokos C, Kaiafa GD, Tsartsalis DN, Kattamis A, Hatzitolios AI, Savopoulos CG. Hormones (Athens). 2012 Apr-Jun;11(2):126-39. Review IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Athyros VG, Hatzitolios AI, Karagiannis A, Savopoulos C, Katsiki N, Tziomalos K, Papagianni A, Kakafika A, Gossios TD, Mikhailidis DP; IMPERATIVE Collaborative Group. Role of phytosterols in lipid-lowering: current perspectives. Gupta AK, Savopoulos CG, Ahuja J, Hatzitolios AI. QJM. 2011 Apr;104(4):301-8. doi: 10.1093/qjmed/hcr007. Epub 2011 Feb 15. Review. The controversial role of B-vitamins in cardiovascular risk: An update. Ntaios G, Savopoulos C, Grekas D, Hatzitolios A. Arch Cardiovasc Dis. 2009 Dec;102(12):847-54. doi: 10.1016/j.acvd.2009.07.002. Review. Trend in incidence of cardiovascular risk factors in elderly and over-aged stroke patients between 2003 and 2007 in Greece. Kotsaftis P, Ntaios G, Savopoulos C, Kiparoglou R, Agapakis D, Baltatzi M, Tsesmeli N, Hatzitolios A. Arch Gerontol Geriatr. 2010 May-Jun;50(3):e31-5. doi: 10.1016/j.archger.2009.05.002. Epub 2009 Jun 10. An association study between catalase -262C>T gene polymorphism, sodium-lithium countertransport activity, insulin resistance, blood lipid parameters and their response to atorvastatin, in Greek dyslipidaemic patients and normolipidaemic controls. Kosmidou M, Hatzitolios AI, Molyva D, Raikos N, Savopoulos C, Daferera N, Kokkas V, Goulas A. Free Radic Res. 2009 Apr;43(4):385-9. doi: 10.1080/10715760902783293. Epub 2009 Mar 9. Implementation of strategy for the management of overt dyslipidemia: the IMPROVE-dyslipidemia study. Hatzitolios AI, Athyros VG, Karagiannis A, Savopoulos C, Charalambous C